Your browser doesn't support javascript.
loading
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.
Sorbo, Maria C; Cento, Valeria; Di Maio, Velia C; Howe, Anita Y M; Garcia, Federico; Perno, Carlo F; Ceccherini-Silberstein, Francesca.
Afiliación
  • Sorbo MC; Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
  • Cento V; Residency program in Microbiology and Virology, Università degli Studi di Milano. Milan, Italy. Electronic address: valeria.cento@unimi.it.
  • Di Maio VC; Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
  • Howe AYM; Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada.
  • Garcia F; Clinical Microbiology Service, Hospital Universitario San Cecilio, Granada, Spain.
  • Perno CF; Department of Oncology and Oncohematology, Università degli Studi di Milano. Milan, Italy. Electronic address: carlo.perno@unimi.it.
  • Ceccherini-Silberstein F; Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy. Electronic address: ceccherini@med.uniroma2.it.
Drug Resist Updat ; 37: 17-39, 2018 03.
Article en En | MEDLINE | ID: mdl-29525636
Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available. The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virolgical cure. To date, a high number of RASs in NS3, NS5A, and NS5B have been associated in vivo and/or in vitro with reduced susceptibility to DAAs, but no comprehensive RASs list is available. This review thus provides an updated, systematic overview of the role of RASs to currently approved DAAs or in phase II/III of clinical development against HCV-infection, discriminating their impact in different HCV-genotypes and DAAs, providing assistance for a fruitful use of HCV resistance testing in clinical practice.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Proteínas no Estructurales Virales / Hepacivirus / Hepatitis C Crónica / Farmacorresistencia Viral Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Drug Resist Updat Asunto de la revista: ANTINEOPLASICOS Año: 2018 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Proteínas no Estructurales Virales / Hepacivirus / Hepatitis C Crónica / Farmacorresistencia Viral Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Drug Resist Updat Asunto de la revista: ANTINEOPLASICOS Año: 2018 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido